{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:57:44Z","timestamp":1722837464873},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1208\/s12248-019-0299-9","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T16:05:36Z","timestamp":1552579536000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Receiver Operating Characteristic Framework for Non-adherence Detection Using Drug Concentration Thresholds\u2014Application to Simulated Risperidone Data in Schizophrenic Patients"],"prefix":"10.1208","volume":"21","author":[{"given":"Carlos","family":"P\u00e9rez-Ruixo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Remmerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Per\u00e9z-Ruixo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"299_CR1","unstructured":"World Health Organization. Mental Health, Schizophrenia. 2017. Available from: \n                    http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\n                    \n                  \/. Accessed 13 Nov 2018."},{"issue":"1","key":"299_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013881","volume":"7","author":"D Keating","year":"2017","unstructured":"Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881.","journal-title":"BMJ Open"},{"issue":"10","key":"299_CR3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry."},{"issue":"5","key":"299_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","volume":"2","author":"FJ Acosta","year":"2012","unstructured":"Acosta FJ, Hernandez JL, Pereira J, Herrera J, Rodriguez CJ. Medication adherence in schizophrenia. World J Psychiatry. 2012;2(5):74\u201382.","journal-title":"World J Psychiatry"},{"issue":"2\u20133","key":"299_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","volume":"176","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2\u20133):109\u201313.","journal-title":"Psychiatry Res"},{"issue":"4","key":"299_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"Suppl 4","key":"299_CR7","first-page":"1","volume":"70","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1\u201346 quiz 7-8.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"299_CR8","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","volume":"25","author":"S Karve","year":"2009","unstructured":"Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303\u201310.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"299_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/schbul\/sbj075","volume":"32","author":"DI Velligan","year":"2006","unstructured":"Velligan DI, Lam Y-WF, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724\u201342.","journal-title":"Schizophr Bull"},{"issue":"5","key":"299_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1176\/appi.ajp.2016.16040402","volume":"174","author":"M Horvitz-Lennon","year":"2017","unstructured":"Horvitz-Lennon M, Mattke S, Predmore Z, Howes OD. The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry. 2017;174(5):421\u20136.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"299_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/psp4.12217","volume":"6","author":"J Korell","year":"2017","unstructured":"Korell J, Green B, Remmerie B, Vermeulen A. Determination of plasma concentration reference ranges for risperidone and paliperidone. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):589\u201395.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"299_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000343162","volume":"58","author":"Y Suzuki","year":"2012","unstructured":"Suzuki Y, Kawasaki K, Sato Y, Tokimatsu I, Itoh H, Hiramatsu K, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy. 2012;58(4):308\u201312.","journal-title":"Chemotherapy"},{"issue":"3","key":"299_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s11095-013-1193-2","volume":"31","author":"A Olivares-Morales","year":"2014","unstructured":"Olivares-Morales A, Hatley OJ, Turner D, Galetin A, Aarons L, Rostami-Hodjegan A. The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. Pharm Res. 2014;31(3):720\u201330.","journal-title":"Pharm Res"},{"issue":"11","key":"299_CR14","first-page":"771","volume":"7","author":"JD Clements","year":"2018","unstructured":"Clements JD, Perez Ruixo JJ, Gibbs JP, Doshi S, Perez Ruixo C, Melhem M. Receiver operating characteristic analysis and clinical trial simulation to inform dose titration cecisions. CPT: Pharmacometrics Systems Pharmacol. 2018;7(11):771\u20139.","journal-title":"CPT: Pharmacometrics Systems Pharmacol"},{"issue":"3","key":"299_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","volume":"86","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Gathon H-J, Ethgen O, Reginster J-Y. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010;86(3):202\u201310.","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"299_CR16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.ophtha.2013.01.002","volume":"120","author":"DS Chang","year":"2013","unstructured":"Chang DS, Friedman DS, Frazier T, Plyler R, Boland MV. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Ophthalmology. 2013;120(7):1396\u2013402.","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"299_CR17","first-page":"S83","volume":"29","author":"CM Florkowski","year":"2008","unstructured":"Florkowski CM. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev. 2008;29(Suppl 1):S83\u20137.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"299_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3348\/kjr.2004.5.1.11","volume":"5","author":"SH Park","year":"2004","unstructured":"Park SH, Goo JM, Jo CH. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol. 2004;5(1):11\u20138.","journal-title":"Korean J Radiol"},{"issue":"2","key":"299_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10928-006-9040-2","volume":"34","author":"A Vermeulen","year":"2007","unstructured":"Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn. 2007;34(2):183\u2013206.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"299_CR20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","volume":"39","author":"MH Zweig","year":"1993","unstructured":"Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561\u201377.","journal-title":"Clin Chem"},{"issue":"4","key":"299_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0001-2998(78)80014-2","volume":"8","author":"CE Metz","year":"1978","unstructured":"Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8(4):283\u201398.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"299_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1037\/0033-2909.99.1.100","volume":"99","author":"JA Swets","year":"1986","unstructured":"Swets JA. Indices of discrimination or diagnostic accuracy: their ROCs and implied models. Psychol Bull. 1986;99(1):100\u201317.","journal-title":"Psychol Bull"},{"issue":"1","key":"299_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","volume":"143","author":"JA Hanley","year":"1982","unstructured":"Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29\u201336.","journal-title":"Radiology"},{"key":"299_CR24","first-page":"113","volume-title":"Evidence-based laboratory medicine; principles, practice and outcomes","author":"JC Boyd","year":"2007","unstructured":"Boyd JC. Statistical analysis and presentation of data. In: Price CP, editor. Evidence-based laboratory medicine; principles, practice and outcomes. 2nd ed. Washington DC, USA: AACC Press; 2007. p. 113\u201340.","edition":"2"},{"issue":"158","key":"299_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209\u201312.","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"299_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJM197507312930501","volume":"293","author":"BJ McNeil","year":"1975","unstructured":"McNeil BJ, Keller E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med. 1975;293(5):211\u20135.","journal-title":"N Engl J Med"},{"issue":"3977","key":"299_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1126\/science.171.3977.1217","volume":"171","author":"LB Lusted","year":"1971","unstructured":"Lusted LB. Signal detectability and medical decision-making. Science. 1971;171(3977):1217\u20139.","journal-title":"Science"},{"issue":"1","key":"299_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"6947","key":"299_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/bmj.309.6947.102","volume":"309","author":"DG Altman","year":"1994","unstructured":"Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ. 1994;309(6947):102.","journal-title":"BMJ"},{"key":"299_CR30","volume-title":"7.1.0 Users Guides","author":"NONMEM","year":"1989","unstructured":"NONMEM. 7.1.0 Users Guides. Icon Development Solutions: Ellicott City, MD; 1989-2009."},{"key":"299_CR31","volume-title":"R: A language and environment for statistical computing","author":"R Development Core Team","year":"2012","unstructured":"R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012."},{"issue":"5","key":"299_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/jmri.21947","volume":"30","author":"RH Khouli El","year":"2009","unstructured":"El Khouli RH, Macura KJ, Barker PB, Habba MR, Jacobs MA, Bluemke DA. Relationship of temporal resolution to diagnostic performance for dynamic contrast enhanced MRI of the breast. J Magn Reson Imaging. 2009;30(5):999\u20131004.","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"299_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/02841850500539033","volume":"47","author":"L Ludemann","year":"2006","unstructured":"Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Glioma assessment using quantitative blood volume maps generated by T1-weighted dynamic contrast-enhanced magnetic resonance imaging: a receiver operating characteristic study. Acta Radiol. 2006;47(3):303\u201310.","journal-title":"Acta Radiol"},{"issue":"5 Pt 1","key":"299_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0013-7006(05)82420-0","volume":"31","author":"E Mannaert","year":"2005","unstructured":"Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron JC. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Enc\u00e9phale. 2005;31(5 Pt 1):609\u201315.","journal-title":"Enc\u00e9phale"},{"key":"299_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.schres.2018.05.028","volume":"201","author":"R Melkote","year":"2018","unstructured":"Melkote R, Singh A, Vermeulen A, Remmerie B, Savitz A. Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophr Res. 2018;201:324\u20138.","journal-title":"Schizophr Res"},{"issue":"12","key":"299_CR36","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40262-017-0552-2","volume":"56","author":"A Morrison","year":"2017","unstructured":"Morrison A, Stauffer ME, Kaufman AS. Relationship between adherence rate threshold and drug \u2018forgiveness\u2019. Clin Pharmacokinet. 2017;56(12):1435\u201340.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"299_CR37","doi-asserted-by":"publisher","first-page":"e12-e","DOI":"10.4088\/JCP.12045tx2c","volume":"74","author":"JM Kane","year":"2013","unstructured":"Kane JM. Tools to assess negative symptoms in schizophrenia. J Clin Psychiatry. 2013;74(6):e12-e.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"299_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10928-015-9439-8","volume":"42","author":"K Fellows","year":"2015","unstructured":"Fellows K, Stoneking CJ, Ramanathan M. Bayesian population modeling of drug dosing adherence. J Pharmacokinet Pharmacodyn. 2015;42(5):515\u201325.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-019-0299-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:25:24Z","timestamp":1584059124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-019-0299-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1208\/s12248-019-0299-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"19 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors are employees of Janssen Research & Development, LLC, and may hold stock options or shares in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"40"}}